The current study investigates the activation in vivo and regulation of the expression of components of the p38 mitogen-activated protein kinase (MAPK) pathway during gonadotropin-induced formation and development of the rat corpus luteum, employing a sequential PMSG/human CG (hCG) treatment paradigm. We postulated that the p38 MAPK pathway could serve to promote phosphorylation of key substrates during luteal maturation, since maturing luteal cells, thought to be cAMPnonresponsive, nevertheless maintain critical phosphoproteins. Both p38 MAPK and its upstream activator MAPK kinase-6 (MKK6) were found to be chronically activated during the luteal maturation phase, with activation detected by 24 h post hCG and maintained through 4 days post hCG. The p38 MAPK downstream protein kinase target termed MAPK-activated protein kinase-3 (MAPKAPK-3) was newly induced at both mRNA and protein levels during luteal formation and maturation, while mRNA and protein expression of the closely related MAPKAPK-2 diminished. Two potential substrates for MAPKAPKs, the small heat shock protein HSP-27 and the cAMP regulatory element binding protein CREB, were monitored in vivo for phosphorylation. HSP-27 phosphorylation was not modulated during luteal maturation. In contrast, we observed sustained luteal-phase CREB phosphorylation in vivo, consistent with upstream MKK6/p38 MAPK activation and MAPKAPK-3 induction. MAPKAPK-3-specific immune complex kinase assays provided direct evidence that MAPKAPK-3 was in an activated state during luteal maturation in vivo. Cellular inhibitor studies indicated that an intact p38 MAPK path was required for CREB phosphorylation in a cellular model of luteinization, as treatment of luteinized granulosa cells with the p38 MAPK inhibitor SB 203580 strongly inhibited CREB phosphorylation. Transient transfection studies provided direct evidence that MAPKAPK-3 was capable of signaling to activate CREB transcriptional activity, as assessed by means of GAL4-CREB fusion protein construct coexpressed with GAL4-luciferase reporter construct. Introduction of wild-type, but not kinase-dead mutant, MAPKAPK-3 cDNA, into a mouse ovarian cell line stimulated GAL4-CREBdependent transcriptional activity approximately
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INTRODUCTION
Mitogen-activated protein kinases (MAPKs) comprise a superfamily of kinases activated in response to mitogenic, stressful, and differentiation-inducing stimuli (reviewed in Ref. 1) . MAPKs are recognized to regulate cellular responses both through the phosphorylation of transcription factors, and through the phosphorylation/activation of downstream target protein kinases. The mammalian MAPK superfamily contains at least three subgroups, the extracellular-regulated kinases (ERK/MAPKs), the stress-activated protein kinases/ Jun kinases (SAPK-1/Jun kinases), and the p38 MAPKs, orthologs of the yeast osmosensitive HOG-1 kinase. Upstream MAPK-kinases (MKKs) MKK6 and MKK3 serve to activate p38 MAPK through phosphorylation (2, 3) . Once activated, p38 MAPK then phosphorylates, and may thereby activate, a number of substrates including two closely related downstream target kinases called mitogen-activated protein kinase-activated protein kinases-2 and -3 (MAPKAPK-2 and MAPKAPK-3) (4) (5) (6) (7) (8) . These MAPKAPKs, in turn, phosphorylate a set of substrates that include both the small heat shock protein HSP-27 (9, 10) and the nuclear transcription factor, cAMP-response element binding protein (CREB), on the activation-related site serine 133 (11) (12) (13) .
Activation of both p42/p44 ERK/MAPK and p38 MAPK has been documented during ovarian response to hormonal stimulation. ERK/MAPK activation is elicited by treatment of granulosa cells with epidermal growth factor (14) , FSH (15) (16) (17) , or LH (16) , and in luteal cells by treatment with PGF2␣ (18) . The consequent phosphorylation/activation of the downstream ERK/MAPK target protein kinase p90 rsk was demonstrated in FSH-treated immature rat granulosa cells (15) (19, 20) , with resultant phosphorylation of the MAPKAPK-2/-3 substrate HSP-27 and modulation of cell shape (19) , and UV light, a stress stimulus, activates p38 MAPK in bovine luteal cells (21) .
In the rat, activation of preovulatory follicular granulosa cell LH receptors by the proestrus LH surge, or by pharmacological treatment with the LH receptor agonist, human CG (hCG), causes ovulation and differentiation of the ovulated follicle into a corpus luteum. LH/hCG-induced ovulation and luteal formation are accompanied by a pattern of distinct biochemical changes (reviewed in Ref. 22) , including, for example, down-regulation followed by later reappearance of the LH receptor and aromatase, the transient induction of the progesterone receptor, the induction of PGHsynthase-2, and the down-regulation of inhibin ␣ expression. Protein phosphorylation is recognized to be a key ovarian response to hormonal stimulation. LH/hCG-induced cAMP formation and consequent protein kinase A (PKA)-mediated phosphorylation of target proteins are required for both ovulation and luteal formation. However, once luteal formation is initiated, the mechanism for the LH/hCG-stimulated cAMP production becomes desensitized (23), the requirement for continued cAMP-dependent signaling is lost, and a state of cAMP nonresponsiveness is thought to characterize the maturing luteal cell (24, 25) . Nevertheless, phosphorylation of luteal proteins, notably CREB, remains evident (25) ; therefore, kinases other than PKA would be expected to control phosphorylation of target proteins during luteal maturation. Based on our evidence that the p38 MAPK pathway is required for immature granulosa cell response to FSH (19) and that this pathway is known to be regulated by a large number of input signals from many G proteincoupled receptors as well as growth factor receptors in other cellular models (1), we postulated that the p38 MAPK path would serve to phosphorylate essential targets during the cAMP-nonresponsive luteal maturation phase. We undertook to examine components of the p38 MAPK pathway for evidence of regulation during hCG-induced luteal maturation with special interest in MAPKAPKs, as those kinases could regulate the phosphorylation of CREB (11) (12) (13) 26) . We found that expression of MAPKAPKs was inversely regulated. While MAPKAPK-2 expression diminished with luteal development, MAPKAPK-3 was newly induced during this developmental transition. Moreover, MAP-KAPK-3 induction was accompanied by upstream kinase activation, and by downstream substrate phosphorylation; thus, MAPKAPK-3 is uniquely poised to subserve the role of critical kinase during luteal maturation.
RESULTS

Activation of Ovarian p38 MAPK and MKK3/6 in Vivo during Hormone-Induced Luteinization
We investigated the activation states of upstream component kinases in the p38 MAPK cascade in vivo during hormone-induced follicle maturation, ovulation, and luteinization in the rat. Immature rats were subjected to the well characterized sequential gonadotropin-induced luteinization paradigm (27) , comprised of initial subcutaneous PMSG injection to induce follicular maturation to the preovulatory stage, followed 48 h later by subcutaneous hCG injection to induce ovulation and luteinization.
p38 MAPK, analogous with other MAPK family members (1) , is activated by dual phosphorylation on threonine and tyrosine within the TXY motif in the activation loop (28) . For p38 MAPK, these phosphorylations are catalyzed by upstream dual-specificity kinases, the MAPK-kinases MKK6 and MKK3 (2, 3) . In turn, these MKKs are activated by phosphorylation on homologous serine and threonine residues (29) . We tracked the phosphorylation states of these phosphorylation-dependent kinases as a measure of their activation states, by means of immunoblotting with phospho-specific antibodies.
First, immunoblots were performed on ovarian lysates prepared from rats at various times post PMSG and hCG injections to detect activation of MKK6 and MKK3 by using a phospho-specific antibody that recognizes activation-specific phosphorylation sites (29) , phosphoserine 207 of MKK6 and the corresponding phosphoserine 189 of MKK3, respectively (Fig. 1, upper panel) . Protein levels were determined by immunoblotting with control antibodies specific for MKK6 and MKK3 (Fig. 1 , middle and lower panels, respectively). Both the 35-kDa MKK3 and the 37-kDa MKK6 showed a small degree of activation by 1 h in response to both PMSG (Fig. 1, top panel, lane 2) and hCG (lane 6) in follicular and periovulatory phases. However, while MKK3 failed to show sustained activation as luteal maturation progressed (Fig. 1,  lanes 9-12) , strong sustained activation of the 37-kDa MKK6 accompanied luteal maturation (Fig. 1, top panel,  lanes 8-12) .
Next, immunoblots were performed on ovarian lysates prepared at various times post PMSG and post hCG injections to detect activation of p38 MAPK using a phospho-specific antibody that recognizes the activated form ( Fig. 2A, upper panel) . Protein levels were determined by immunoblotting with control antibody specific for p38 MAPK ( Fig. 2A, lower panel) . p38 MAPK showed a small degree of activation in response to PMSG in the follicular phase ( Fig. 2A , top panel, lane 2). p38 MAPK underwent strong biphasic activation in response to hCG, with initial acute activation 1 h post hCG (Fig. 2A, lane 6) , and a second sustained chronic activation phase accompanying luteal maturation ( Fig. 2A, lanes 8-11) .
Finally, to compare and contrast the activation pattern of p38 MAPK with that of the well characterized ERK/MAPKs, immunoblots to detect activation (phosphorylation-specific antibody, Fig. 2B, upper panel) , as well as protein expression of ERK/MAPKs (control antibody, Fig. 2B , lower panel), were performed on ovarian lysates prepared at various times post PMSG and post hCG injections. ERK/MAPK displayed slight activation post PMSG in the follicular phase (Fig. 2B , lane 3). Strong acute ERK/MAPK activation was detected at 1 h post hCG in a manner similar to p38 MAPK; however, ERK/MAPKs failed to undergo a second sustained activation phase as luteal maturation progressed. The lack of a second sustained luteal ERK/MAPK activation phase suggests that, unlike p38 MAPK, the ERK/MAPKs are not poised to participate in phosphorylation events during luteal maturation.
Inverse Modulation of MAPKAPK-2 and MAPKAPK-3 Expression Accompanying Hormone-Induced Follicular Maturation and Luteinization
We proceeded to investigate the ovarian pattern of expression of the two related p38 MAPK target protein kinases, MAPKAPK-2 and MAPKAPK-3, in vivo during hormone-induced follicle maturation, ovulation, and luteinization. We studied alterations in ovarian expression of each MAPKAPK at various time points post PMSG injection or post hCG injection.
First, immunoblots to detect protein expression of both MAPKAPKs were performed on ovarian lysates prepared at various times post PMSG and post hCG injections. As seen in Fig. 3A , MAPKAPK-2 protein, detected as two isoforms at 47 and 54 kDa (30, 31) , was abundant at early time points throughout follicular maturation (lanes 1-8), and then decreased markedly at later time points post ovulation, as luteal maturation progressed (lanes 9-12). In contrast to the decreased expression of MAPKAPK-2 noted above, MAPKAPK-3 protein expression, detected at 42 kDa, was minimal at early time points during follicular development (Fig.  3B, lanes 1-7) , and was strongly induced as luteal maturation progressed, increasing from 33 h post hCG onward through the end of the observation period. (Fig. 3B, lanes 8-11) .
Next, ovarian slices obtained from rats at various times post hCG injection were subjected to in situ hybridization using cRNA probes specific to each MAPKAPK, respectively, to detect mRNA expression. MAPKAPK-2 mRNA signal (Fig. 4A, top panel) , detected in the earliest time points post hCG (weakly at 0 and more strongly at 1 and 8 h post hCG), diminished in the luteal phase slices (24 h and 33 h post hCG), indicating that loss of MAPKAPK-2 mRNA expression preceded the loss of MAPKAPK-2 protein expression observed during the luteal maturation phase (Fig. 3A) . In contrast, MAPKAPK-3 mRNA signal ( (Fig. 3B ). Hybridization with a cRNA probe specific for inhibin ␣ was performed on the same slices to serve as a control to verify ovarian response to hCG, since expression of inhibin ␣, prominent in preovulatory follicles, is recognized to decrease during gonadotropin-induced ovulation and luteinization (32) . As expected, inhibin ␣ mRNA expression was strongly evident in follicular structures in 0 and 1 h post hCG slices and diminished thereafter (Fig. 4A , bottom panel).
Phosphorylation State of MAPKAPK Substrates in Vivo: HSP-27
In light of the striking expression changes in ovarian MAPKAPKs during follicular maturation and luteinization and in light of clear evidence of in vivo upstream MKK6/p38 MAPK activation accompanying luteal maturation, we wished to evaluate the phosphorylation state of known MAPKAPK substrates for evidence of modulated phosphorylation in vivo. Two well recognized MAPKAPK substrates were considered: CREB (see section below) and HSP-27 (6, 8, 33) .
The small heat shock protein HSP-27 from rodent sources can be phosphorylated by MAPKAPKs on two potential phosphorylation sites corresponding to serine 15 and serine 86 (34) . Phosphorylation on one or both of these sites results in the appearance of HSP-27 phosphoisoforms displaying distinct migration positions on two-dimensional isoelectric focusing (IEF)/SDS PAGE gels (19, 35) . Two-dimensional immunoblots, to detect phosphoisoforms of HSP-27 as a measure of in vivo HSP-27 phosphorylation state, were performed on ovarian lysates prepared at various times post PMSG and post hCG injections. As seen in Fig. 5 (top), all two-dimensional blots displayed spots corresponding to basic unphosphorylated HSP-27 isoforms (designated by arrowhead a), more acidic monophosphorylated HSP-27 phosphoisoforms (designated by arrowheads b and bЈ), and diphosphorylated HSP 27 phosphoisoforms (designated by arrowhead c), with no detectable alteration in HSP-27 phosphoisoform content. We calculated relative HSP-27 phosphorylation levels from observed densities of spots corresponding to mono-or diphosphorylated HSP-27 phosphoisoforms (Fig. 5, bottom) . No modulation of HSP-27 phosphorylation levels was observed in ovarian lysates obtained during either follicular or luteal phases of development. Thus, the phosphorylation state of HSP-27 did not correlate with the activation state of the p38 MAPK/MAPKAPK-3 axis during the luteal phase; however, HSP-27 phosphorylation could be maintained at constant levels by alternative mechanisms, e.g. through phosphorylation by other recognized HSP-27 kinases (35), or alternatively through the action of HSP-27 phosphatases (36, 37) . We have recently observed that the ␦ isoform of protein kinase C (PKC-␦), an efficient HSP-27 kinase (35), is detected in ovarian extracts in a constitutively activated state during luteinization (L. M. Salvador, E. Maizels, E. Miyamoto, H. Yamamoto, and M. Hunzicker-Dunn, in preparation) and would account for the constant phosphorylation of HSP-27 during this transition.
Phosphorylation/Activation of CREB in Vivo, in Vitro, and in Cellular Models
The nuclear transcription factor CREB has been reported to be a substrate for both MAPKAPK-2 and MAPKAPK-3 (11-13), with phosphorylation on the activation-regulating site serine 133. We evaluated CREB as a potential target for the p38 MAPK/ MAPKAPK pathway in the ovary in vivo, in vitro in immune complex kinase assays, by pharmacological studies in a cellular model of luteinization, and by transfection assays using a CREB-sensitive reporter.
We evaluated the phosphorylation state of CREB in vivo during hormone-induced follicle maturation, ovulation, and luteinization. Immunoblots were performed on ovarian lysates prepared at various times post PMSG and post hCG injections to detect phosphorylation of CREB using a phospho-specific antibody that recognizes CREB phosphorylated on serine 133 (Fig. 6, upper  panel) . Protein levels were determined by immunoblotting with control antibody specific for CREB (Fig. 6, lower  panel) . Increased phosphorylation of CREB on serine 133 was detected in response to PMSG treatment (Fig.  6, lanes 2 and 3) . Additionally, CREB underwent biphasic phosphorylation in response to hCG. Phosphorylation of CREB increased acutely at 1 h post hCG (Fig. 6, lane 6 ), decreased to a nadir at 8 h post hCG (Fig. 6, lane 7) , and then began to rise again by 48 h post hCG (Fig. 6, lane 9) . Densitometric values normalized for protein content, shown graphically in the lower section of Fig. 6 , indicated that CREB phosphorylation levels had risen to approximately one third the maximal value by 48 h post hCG, a level compatible with the extent of induction of MAPKAPK-3 that has occurred at this time. Strong CREB phosphorylation was maintained as luteal maturation progressed (Fig. 6, lanes 10-12) . The sustained CREB phosphorylation observed during later time points of luteal maturation is consistent with CREB functioning as an in vivo phosphorylation target for the newly induced MAPKAPK-3.
Upstream kinase activation, as well as downstream substrate phosphorylation, provided correlative evidence that MAPKAPK-3 would be found in an activated state during luteal maturation. We sought direct evidence for activation of MAPKAPK-3 in vivo during luteal maturation by use of a MAPKAPK-3-specific immune complex kinase assay protocol (8) . MAPKAPK-3 is activated by p38 MAPK-catalyzed phosphorylation on threonines 201 and 313 (8) . Immunoprecipitations with MAPKAPK-3-specific antibody were performed in the presence of phosphatase inhibitors to maintain the phosphorylation/activation state of MAPKAPK-3 that had been achieved in vivo. The collected immune complexes were assayed for kinase activity by incubation with recombinant CREB as substrate in the presence of [␥-
32 P]ATP, and the resulting 32 P incorporation into CREB was demonstrated by SDS-PAGE and autoradiography. Assays were performed on MAPKAPK-3 immune complexes collected from ovarian extracts obtained at various times post hCG injection in vivo (Fig. 7A) . Results showed that there was minimal [ 32 P]phosphate incorporation into CREB by immune complexes prepared from early time points (0 and 1 day post hCG) consistent with the low level of MAPKAPK-3 protein expression at these times. In contrast, immune complexes collected at later time points during the luteal maturation phase (2 and 4 days post hCG) catalyzed increased [
32 P]phosphate incorporation into CREB, indicating sustained activation of MAPKAPK-3 accompanying luteal maturation. Control immune complexes, collected either in the absence of MAPKAPK-3 antibody or in the absence of ovarian extract, showed no detectable phosphorylation of CREB (Fig. 7A, right panel) . These assay results provide direct evidence that newly induced MAPKAPK-3 undergoes sustained activation in vivo during luteal maturation, consistent with sustained activation of upstream kinases MKK6 and p38 MAPK, and the sustained phosphorylation of CREB. Additionally, these immune complex kinase assays confirmed previous reports indicating that MAPKAPK-3 can directly phosphorylate CREB in vitro (12, 26) . In light of the correlation of MAPKAPK-3 induction and activation with CREB phosphorylation during luteal maturation in vivo, we wished to evaluate the extent to which p38 MAPK-dependent events might contribute to CREB phosphorylation in a luteal context. The pyridinyl imidazole SB 203580, a competitive p38 MAPK inhibitor that binds to the ATP binding site and thereby inhibits catalytic activity (38, 39) , is widely used in cell studies to demonstrate the involvement of the p38 MAPK pathway in cellular events. Luteinized granulosa cells, collected and cultured according to a protocol similar to that employed by GonzalezRobayna et al. (25) , provided a suitable cellular model of luteinization for evaluating the effects of pharmacological p38 MAPK inhibition, as luteinized granulosa cells express MAPKAPK-3 (Fig. 7B, left panel) , and these cells have previously been reported to show persistent CREB phosphorylation in a cAMP-nonresponsive manner (25) . Luteinized granulosa cells were treated with or without p38 MAPK inhibitor SB 203580 for 4 h and then harvested and analyzed for CREB phosphorylation by immunoblotting. As seen in Fig.  7B , right panel, CREB serine 133 phosphorylation was prominent in control cells and was markedly reduced by treatment with SB 203580. These data are consistent with CREB phosphorylation being a p38 MAPK pathway-dependent event in this cellular model of luteinization.
A recent immunofluorescence study of cultured luteinized granulosa cells found phosphorylated CREB largely in the soluble compartment, a compartment in which transcriptional function of phosphorylated CREB would be abrogated, rather than the expected nuclear compartment in which phosphorylated CREB functions as a transcription factor (25) . Based on the results of that study, we wished to identify the subcellular localization of phosphorylated CREB in our in vivo luteinization model. Ovarian extracts obtained at various times post hCG injection in vivo were separated by centrifugation into soluble fractions and nuclear enriched-particulate fractions, respectively. We additionally prepared soluble and nuclear enriched-particulate fractions from luteinized granulosa cells to serve as controls. Immunoblots to visualize phosphorylated CREB were performed on both soluble and nuclearenriched particulate fractions (Fig. 7C) . Results showed that luteinized granulosa cells displayed phosphorylated CREB primarily in the soluble fraction (Fig. 7C, lane 7) , confirming the report of GonzalesRobayna et al. (25) . Notably in contrast, phosphory- lated CREB was localized to the nuclear-enriched particulate fraction at all time points examined using the in vivo luteinization protocol (Fig. 7C, lanes 2, 4, and 6 ). Thus, phosphorylated CREB was retained in a functional compartment in vivo during luteal maturation.
In light of the temporal correlation of upstream kinase activation, MAPKAPK-3 expression and activation, and sustained CREB serine 133 phosphorylation during luteal maturation, we wished to directly evaluate the ability of MAPKAPK-3 to modulate CREB transcriptional activity in ovarian cells. We employed the sensitive GAL4-linked CREB transcriptional activity assay system (40, 41) . This assay system measures GAL4-driven transcription activated in response to phosphorylation of the activating serine residue (corresponding to serine 133) of the CREB moiety within a fusion protein comprised of full-length CREB linked to the DNA-binding region of the yeast transcription factor GAL4. GRMO2 cells, representing a stable mature granulosa cell line (42) , were cotransfected with MAPKAPK-3 cDNAs together with CREB-GAL4 fusion protein expression vector and GAL4 binding site-luciferase reporter gene construct (Fig. 8) . Cotransfection with 50 ng wild-type MAPKAPK-3 cDNA increased CREB-GAL4-mediated reporter activity, to levels approximately 3-fold over basal activity seen with empty vector, a modest but significant increase (P Ͻ 0.05, Fig. 8) . Notably, the modest reporter activity achieved by MAPKAPK-3 in the absence of exogenous p38 MAPK activators likely represents partial activation of wild-type MAPKAPK-3 supported by inclusion of serum in GRMO2 culture medium, as serum serves as only a mild activator for MAPKAPK-3 (8). The strong p38 MAPK activators anisomycin and arsenite were tested as exogenous agents that might further activate MAP-KAPK-3; however, these treatments were toxic to GRMO2 cells at the concentrations required to activate p38 MAPK and thus could not be further evaluated. CREB-GAL4-mediated reporter activity in the presence of wild-type MAPKAPK-3 corresponded to approximately 60% of that achieved through activation of PKA in the presence of forskolin, and approximately 20% of that achieved through transfection of PKA catalytic subunit cDNA (not shown). Importantly, in contrast to wild-type MAPKAPK-3 cDNA, 50 ng of the kinase-dead KϾM MAPKAPK-3 mutant cDNA (8) failed to support increased CREB-GAL4-mediated reporter activity, indicating that the kinase activity of MAPKAPK-3 is necessary for the positive effect of MAPKAPK-3 on CREB transcriptional activity. Thus MAPKAPK-3 can signal to enhance CREB transcriptional activity in ovarian cells in a kinase-dependent manner, i.e. through phosphorylation. Based on the results of these cotransfection experiments, MAPKAPK-3 induced during luteal maturation in vivo would be capable of signaling to enhance CREB transcriptional activity through phosphorylation.
DISCUSSION
It is well established that the preovulatory surge of LH, which is required for ovulation and luteinization of follicular cells to form the corpus luteum, promotes the expression of a number of genes in a time-dependent manner as well as the repression of other genes (reviewed in Refs. 22 and 43). LH, in common with FSH, is well recognized to promote activation of adenylyl cyclase to generate cAMP, with the resultant activation of PKA and the phosphorylation of PKA substrates. Additionally, kinases other than PKA would carry out critical phosphorylation during luteal maturation, a time when luteal cells are thought to be cAMP-nonresponsive (24, 25) . Based on the known role of the p38 MAPK path in FSH signaling (19) , and based on the known function of the p38 MAPK-activated MAPKAPKs as CREB kinases, we examined ovarian expression and activation patterns for the p38 MAPK cascade in vivo, employing the sequential PMSG-and hCG-induced luteinization paradigm. We found that an inverse pattern of MAPKAPK expression accompanied luteinization, as MAPKAPK-2 expression diminished when MAPKAPK-3 appeared. MAPKAPK-3, newly induced during luteal maturation, is positioned to support critical luteal phosphorylation.
MAPKAPK-2 (44) and -3 (6, 7) are closely related kinases with 75% amino acid sequence homology (7), and shared structural features that include corresponding N-terminal SH3 binding domains, C-terminal nuclear localization sequences, C-terminal ␣-helices, and analogous activating phosphorylation sites (7) . The mechanism of activation has been defined for MAPKAPK-2: phosphorylation of activating sites by p38 MAPK (45) induces a conformational change that moves the inhibitory C-terminal ␣ helix-regulatory region away from the kinase catalytic domain, resulting in activation (46) . Conservation of the involved structures in MAPKAPK-3 (7) suggests that the mechanism of activation would be comparable. MAPKAPK-2 and -3 share common upstream activators and overlapping (6, 8, 12) , although not identical (7), substrate specificities. Indeed, MAPKAPK-2 and MAPKAPK-3 have often been treated as interchangeable (47, 48) . However, the striking inverse pattern of expression of MAPKAPKs during follicle maturation, ovulation, and subsequent luteal development in the rat suggests that these enzymes may, in fact, play unique rather than interchangeable roles in the ovary.
Upstream components of the p38 MAPK cascade displayed discrete patterns of activation in response to gonadotropin treatments in vivo. p38 MAPK underwent initial activation in response to both PMSG and hCG, as well as a sustained chronic activation phase accompanying luteal maturation. Initial responses to PMSG and hCG were accompanied by activation of upstream MKKs MKK3 and MKK6, while the luteal phase response was accompanied by activation of MKK6 exclusively. The initial modest follicular phase activation of p38 MAPK in response to PMSG is consistent with the previous finding that FSH could stimulate p38 MAPK activation in immature rat granulosa cells (19, 20) . The initial acute activation of p38 MAPK in response to hCG activation is interesting and is consistent with the possibility that p38 MAPK-dependent signaling may participate in the mediation or modulation of hCG-stimulated events critical to ovulation, such as the induction of PG synthase-2 or progesterone receptor (43, 49, 50) . The sustained chronic activation of p38 MAPK during luteal maturation would provide for the observed sustained activation of the newly induced luteal kinase MAPKAPK-3, as monitored by immune complex kinase assays.
What stimuli support extended p38 MAPK activation and thus MAPKAPK-3 activation during luteal maturation in the ovary in vivo? While the gonadotropins FSH and hCG indeed elicit acute activation of p38 MAPK in immature and preovulatory granulosa cells, respectively (Refs. 19 and 20; L. M. Salvador, E. Maizels, E. Miyamoto, H. Yamamoto, and M. Hunzicker-Dunn, in preparation), and treatment with hCG elicited p38 MAPK activation acutely in the periovulatory period in the current study, hCG would be unlikely to be responsible for prolonged luteal phase activation, as LH receptors would have undergone both desensitization and down-regulation in response to the ovulatory stimulus (23) . In addition to gonadotropins, a number of cytokines and growth factors are recognized to participate in control of ovarian function (51, 52) . Interleukin-1␤ (IL-1␤), a cytokine known to elicit p38 MAPK activation in target cells (53) , is transiently induced in the periovulatory period (54) (55) (56) and may participate in the periovulatory activation of p38 MAPK. However, IL-1␤ levels have fallen by 48 h post hCG (54) , and thus this cytokine would be unlikely to represent the prolonged luteal-phase p38 MAPK stimulus. The growth factors insulin-like growth factor-1 (IGF-I) and fibroblast growth factor (FGF) can each elicit p38 MAPK/MAPKAPK activation leading to CREB phosphorylation in other experimental systems (11, 13) , suggesting that these growth factors would be capable of serving as initiating stimuli during luteal maturation. IGF-I is well recognized to synergize with gonadotropins to elicit granulosa cell function and differentiation (52, 57) . Moreover, IGF-I receptor levels (58) and basic FGF levels (59) are elevated during early luteal development in the rat. Finally, the proangiogenic growth factor vascular endothelial growth factor (VEGF), a critical factor in corpus luteum formation and growth (60) (61) (62) (63) , is appreciated to activate p38 MAPK in target cells (64) . Thus, the growth factors IGF-I, FGF, and VEGF comprise a set of likely candidates for luteal-phase stimulus to support the prolonged activation of p38 MAPK and MAPKAPK-3. Further experiments will focus on delineating the contribution of each of these critical growth factors.
CREB was evaluated as a potential ovarian target for newly induced and activated MAPKAPK-3 during luteal maturation. The nuclear transcription factor CREB requires phosphorylation on serine 133 to bind the coactivator CREB-binding protein (CBP) and recruit transcriptional machinery (65) . CREB was initially described as a PKA substrate (66) ; however, CREB is now recognized to serve as a phosphorylation target for a number of distinct kinases in several diverse signaling pathways. Several groups have demonstrated CREB serine 133 phosphorylation catalyzed by kinases downstream of activated p38 MAPK (11, (67) (68) (69) . p38 MAPK-dependent CREB phosphorylation was catalyzed by MAPKAPK-2 or a closely related kinase such as MAPKAPK-3 in FGF-treated fibroblasts (11) , and by MAPKAPK-3 in IGF-I-treated PC12 cells (13) . Moreover, MAPKAPK-3 readily phosphorylates CREB in vitro (12, 26) , a finding we have confirmed in the current study through immune complex kinase assays.
CREB underwent clear phosphorylation coinciding with the induction of and activation of MAPKAPK-3. We observed three peaks of CREB phosphorylation in vivo, the first during hormone-induced follicular maturation, the second acute peak in response to hCG in the periovulatory follicle, and the third chronic peak during luteal maturation. The first and second peaks of CREB phosphorylation correspond to previously described cAMP-responsive PKA-mediated events (25, 70, 71) . In contrast, the third luteal-phase CREB phosphorylation represents what is thought to be a cAMPnonresponsive event (25) ; therefore, this phase of phosphorylation is expected to be catalyzed by a CREB kinase other than PKA. Notably, we detected substantial sustained phosphorylation of CREB accompanying the increased expression and activation of MAPKAPK-3 as well as the activation of upstream kinases MKK6/p38 MAPK as luteal maturation progressed.
To further delineate the role of the p38 MAPK pathway in CREB phosphorylation during luteinization, we performed additional studies with the p38 MAPK inhibitor SB 203580 (38) . We found that SB 203580 strongly inhibited CREB phosphorylation in luteinized granulosa cells. These studies are consistent with a requirement for p38 MAPK-mediated signaling events in CREB phosphorylation in this luteal model, in good agreement with in vivo luteal maturation phase profiles. However, it has been suggested recently that p38 inhibitor SB 203580 can impact other signaling pathways in addition to p38 MAPK. Specifically, SB 203580 can impact signaling through ERK (72) and phosphatidylinositol-3 kinase/Akt pathways (73, 74) either through direct interaction with other kinases (72, 73) or through inhibition of cross-talk between p38 MAPK and other kinases (74) . We can detect both ERK and Akt activation in the follicular and periovulatory periods in vivo (Fig. 2B and E . T. Maizels, L. M. Salvador, J. E. Cottom, and M. Hunzicker-Dunn, manuscript in preparation). However, we detect neither ERK nor Akt activation during the luteal maturation phase (48 h to 6 days post hCG); thus neither of these kinase pathway can be implicated in CREB phosphorylation during the luteal maturation phase in vivo (Fig. 2B and E. T. Maizels, L. M. Salvador, J. E. Cottom, and M. Hunzicker-Dunn, manuscript in preparation). In light of the lack of participation of either ERK or Akt in luteal-phase downstream signaling events in vivo, the role of the p38 MAPK path in luteal-phase CREB phosphorylation is unambiguous.
We investigated phosphorylation of an additional MAPKAPK substrate, the small heat shock protein HSP-27. In contrast to CREB, we found no modulation in vivo of the phosphorylation state of HSP-27, a finding that would be explained by the constitutive activation of an alternate HSP-27 kinase, PKC-␦ (35), accompanying ovulation and luteinization (Salvador et al., in preparation).
Findings implicating newly induced MAPKAPK-3 as CREB kinase in vivo and in vitro were reinforced by transfection studies, which yielded direct evidence that MAPKAPK-3 could signal to activate CREB transcriptional activity in a phosphorylation-dependent manner in ovarian cells.
Previous reports indicate that luteal CREB expression and/or function can vary depending on the choice of experimental model of luteinization employed. For example CREB expression is maintained in luteinizing granulosa cells in the rat (25, 70) , although CREB protein expression is completely lost upon luteinization in the primate (75) , indicating that there is species specificity in luteal CREB expression. Additionally, a recent study detected phosphorylated CREB primarily localized to the soluble compartment in luteinized granulosa cells in primary cell culture (25) , a compartment in which phosphorylated CREB would be unable to fulfill its function as a transcription factor. We therefore evaluated the subcellular localization of phosphorylated CREB in our in vivo luteinization model. We were able to confirm that phosphorylated CREB is indeed a soluble protein in cultured luteinized granulosa cells. In contrast, phosphorylated CREB was primarily localized in the nuclear-enriched particulate fraction in the in vivo ovarian samples at all time points, including the 4-day post-hCG time point coinciding with MAPKAPK-3 expression as well as upstream p38 MAPK/MKK6 activation. Thus, phosphorylated CREB is retained in a subcellular compartment compatible with its function as a transcription factor during luteal maturation in vivo.
CREB phosphorylation has been previously implicated in the transcriptional regulation of several important ovarian target genes (43) , making it an interesting potential target for MAPKAPKs in the ovary. It is well established that CREB participates in transcriptional activation of the CYP19 aromatase gene (76, 77) . Aromatase catalyzes the conversion of androgen precursor to estrogen. Aromatase, initially induced by FSH (or PMSG) in granulosa cells of maturing follicles, is lost in response to the ovulatory LH surge (78, 79) but reappears in the corpus luteum by early-to midpregnancy to allow production of estrogen by the maturing corpus luteum (80, 81) . Notably, in an analogous in vivo hCG-stimulated rat luteinization model, aromatase mRNA was induced by 3-day post hCG (82), correlating well with the peak of phosphorylated CREB observed during luteal maturation in our study. The strong temporal correlation indicates aromatase as a potential transcriptional target for MAPKAPK-3-catalyzed CREB phosphorylation accompanying luteal maturation.
In summary, we have described the developmental pattern of regulation of components of the p38 MAPK cascade as ovarian follicles undergo PMSG-induced maturation followed by hCG-induced ovulation, luteal formation, and luteal maturation. The closely related kinases MAPKAPK-2 and MAPKAPK-3 underwent inverse changes in expression level, with loss of MAPKAPK-2 mRNA and protein expression, and induction of MAPKAPK-3 mRNA and protein expression accompanying these developmental transitions. During the luteal maturation phase, MAPKAPK-3 induction was accompanied by sustained activation of upstream activating kinases p38 MAPK and MKK6, and by sustained phosphorylation of its substrate CREB. MAPKAPK-3, activated during luteal maturation in vivo, readily catalyzed CREB phosphorylation in immune complex kinase assays, and phosphorylation of CREB was shown to depend on an intact p38 MAPK signaling pathway in a cellular model of luteinization. Wild-type, but not kinase-dead, MAPKAPK-3 enhanced CREB transcriptional activity in cotransfection studies, demonstrating directly MAPKAPK-3's ability to signal to activate CREB. Thus MAPKAPK-3 is indeed uniquely poised to support luteal maturation through the phosphorylation and activation of the nuclear transcription factor CREB. Further studies will attempt to uncover the stimulus of MKK6/p38 MAPK activation, as well as define transcriptional targets of MAPKAPK-3/CREB during luteal maturation.
MATERIALS AND METHODS
Materials
The following were purchased from indicated vendors or kindly provided by indicated colleagues: MAPKAPK-2 antibody, StressGen Biotechnology (Victoria, British Columbia, Canada); HSP-27 monoclonal antibody, Dr. 
Animals
Sprague Dawley rats (Charles River Laboratories, Inc. Portage, MI) were housed at Northwestern University animal care facilities, maintained in accordance with the "Guidelines for the Care and Use of Laboratory Animals" by protocols approved by the Northwestern University ACUC committee. With the exception of luteinized granulosa cell culture experiments performed as described below, immature female rats (26-27 days old) were injected subcutaneously with 25 IU PMSG. Indicated animals were further injected subcutaneously with 25 IU of hCG 48 h following PMSG injection. Ovaries were harvested at the indicated times post PMSG injection or post hCG injection and either immediately frozen at Ϫ70 C for subsequent in situ hybridization analysis or subjected to tissue extract preparations as described below.
Tissue Extract Preparation
Whole ovarian extracts were prepared by homogenization in lysis buffer (15) containing 10 mM potassium phosphate, pH 7.0, 1 mM EDTA, 5 mM EGTA, 10 mM MgCl 2 , 50 mM ␤-glycerophosphate, 1 mM Na orthovanadate, 2 mM dithiothreitol, 1 mM phenylmethylsulfonyl fluoride, 0.5% NP-40, and 0.1% sodium deoxycholate. A clarified lysate, containing both soluble proteins and detergent-solubilized membrane proteins, was obtained by centrifuging the homogenate at 12,000 ϫ g for 10 min at 4 C. Alternatively, subcellular fractionation was performed by homogenization of ovaries in protease-and phosphatase-inhibitor-enriched homogenization buffer (PPI buffer) as described previously (85), followed by centrifugation at 105,000 ϫ g for 70 min. The separated soluble and nuclear-enriched particulate fractions were prepared for SDS-PAGE by suspension in equal volumes of SDS-containing sample buffer followed by heat denaturation (100 C, 5 min).
Protein concentrations were measured by the method of Lowry et al. (86) using crystalline BSA as a standard.
Luteinized Granulosa Cell Culture
Primary culture of luteinized granulosa cells was performed as previously described (85) . Briefly, immature rats were injected sc with 0.15 IU hCG for 2 days. On the third day, rats were injected sc with 10 IU hCG, and ovaries were removed 7 h post injection. Granulosa cells from large preovulatory follicles were cultured for 9 days in the presence of 1% FBS as described (85) . For inhibitor studies, 9-day cultured cells were removed from serum for 14 h, and then subjected to 4-h treatments with vehicle or 10 M SB 203580, and cell lysates were prepared in the presence of lysis buffer as described in Tissue Extract Preparation. Alternatively, 9-day cultured cells were harvested and homogenized in the presence of PPI buffer and subjected to subcellular fractionation as described above.
Protein Separation
Separation of ovarian lysate proteins was by SDS-PAGE using 10% or 12% separating gels (87) . For two-dimensional gel electrophoresis, ovarian lysate proteins were separated by isoelectric focusing using mixed ampholines (4 parts pH range of 5-8 with 1 part pH range 3-10), and then by SDS-PAGE (87) . For immunoblots, proteins were electrophoretically transferred to Hybond Nitrocellulose C-extra, incubated with primary antibody overnight at 4 C, and detected by enhanced chemiluminescence (Amersham Pharmacia Biotech). Densitometry was analyzed with Molecular Analyst software (Bio-Rad Laboratories, Inc.).
In Situ Hybridization
Twenty-micrometer sections of frozen ovaries were prepared using a Reichert 820 cryostat (AO/Reichert, Buffalo, NY) and mounted onto gelatin-coated glass slides for in situ hybridization as described previously (88) . Hybridization probes used were [ 35 S]UTP-labeled riboprobes derived from the fulllength rat inhibin ␣-subunit cDNA (89, 90) , a 243-bp long fragment of rat MAPKAPK-2 cDNA corresponding to amino acids 119-199 of mouse MAPKAPK-2 (44), and a 216-bp long fragment of rat MAPKAPK-3 isolated by RT-PCR and corresponding to amino acids 267-338 of human MAP-KAPK-3 (7). Hybridization was continued for 12-18 h at 47 C in a humidified chamber. Sense riboprobes were used as controls. Subsequently, the slides were washed to a final stringency of 0.1ϫ SSC at 65 C after a 1 h treatment with 20 g/ml RNAse at 37 C. Slides were then processed for film and emulsion autoradiography (NTB-2, Eastman Kodak Co., Rochester, NY). Exposure time on film was 3 days and on emulsion was 2 weeks. After development of the slides, they were stained with hematoxylin to visualize the nuclei. The sections were then examined and photographed using a microscope (Nikon Optiphot, Nippon Kogaku (USA) Inc., Garden City, NY) or the film autoradiograms were scanned using a Microtek flatbed scanner.
Immune Complex Kinase Assays
Ovarian lysates (500 g protein) were subjected to immunoprecipitation (IP), as described previously (8) , in the presence of 10 l of MAPKAPK-3-specific antibody and 30 l agaroselinked protein AϩG in 500 l incubation volume for 2 h at 4 C. Additional control IPs were done in the absence of antibody (with 4 day post hCG lysate), or with antibody but in the absence of lysate. Complexes were collected by centrifugation, washed three times with RIPA (10 mM Tris-HCl, pH 7.2, 150 mM NaCl, 1.0% deoxycholate, 1.0% Triton X-100, 0.1% SDS, 1 mM Na orthovanadate, 40 g/ml phenylmethylsulfonylfluoride) and then once with TE (10 mM Tris, pH 7.5, 0.1 mM EGTA). Complexes were resuspended in 50 l TE, and assayed for kinase activity for 7 min at 30 C in 115 l reaction volume in the presence of 42 mM ␣-glycerolphosphate, pH 7.0, 8.4 mM MgCl 2 , 0.8 mM dithiothreitol, 42 mM ATP, 4.8 Ci [␥-
32 P]ATP, and 4.8 g purified recombinant CREB. Reactions were terminated by addition of 50 l of SDS stop solution and heat denaturation (100 C, 5 min).
GRMO2 Cell Culture, Transfection, and Luciferase Assays
Cationic liposomes, prepared as described (91) , were used for transient transfection (92) of GRMO2 cells (42) (provided by N.V. Innogenetics, Ghent, Belgium) that were cultured as described (42, 93) in HDTIS (DMEM-F12, 1:1, 10 g/ml insulin, 5 nM sodium selenite, 5 g/ml transferrin, and 100 mg/liter sodium pyruvate) supplemented with 2% FBS in a humidified incubator at 37 C and 5% CO 2 . DNA for transfection was preincubated at room temperature with lipofection reagent for 20-30 min in OptiMEM and then added to cells washed with PBS. GRMO2 cells, grown in 12-well culture dishes, were transfected (per well) with 500 ng of a GAL4 binding site-luciferase reporter plasmid DNA and 50 ng of CREB-GAL4 fusion protein expression construct, and 50 ng of MAP-KAPK-3 constructs (empty MAPKAPK-3 vector, wild-type MAPKAPK-3, or kinase-dead KϾM mutant MAPKAPK-3), as indicated. After 6 h of transfection, the DNA-lipid mixture was replaced with fresh HDTIS containing 2% FBS. Cells were incubated for 12 h, washed with PBS, and then subjected to lysis by gentle agitation on ice in the presence of cell-lysis buffer (25 mM HEPES pH 7.8, 15 mM MgSO 4 , 1 mM dithiothreitol, 0.1% Triton X-100). Luciferase assays were performed essentially as described previously (94) . One hundred microliters of the cell lysates were added to 400 l of assay buffer (25 mM HEPES, pH 7.8, 15 mM MgSO 4 , 5 mM ATP, 1 g/ml BSA), and then 100 l of 1 mM luciferin were added and emitted luminescence was measured using a 2010 luminometer (Analytical Luminescence, San Diego, CA) for 10 sec. Protein content of cell lysates was determined by the Bradford method (95) . Results were analyzed using Student's t test (P Ͻ 0.05) (96) .
